Physician profile
Vincent J Croglio
NPI 1952835977
$25,213.06
in general payments reported to CMS, 2019-2025
26 companies · $9,759 in 2025
The $9,759 reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $495 · 2022: $1,691 · 2023: $5,329 · 2024: $7,938 · 2025: $9,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $9,153 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,750.00 |
| Food and Beverage | $9,152.61 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16,150.98 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,367.85 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,053.34 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $1,007.80 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $768.45 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $748.34 | 2021-2025 | Caplyta |
| Lundbeck LLC | $729.43 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $542.33 | 2021-2025 | Aplenzin, Wellbutrin |
| Neuronetics, INC. | $532.94 | 2023 | Neurostar Tms Therapy System |
| Vanda Pharmaceuticals INC. | $425.86 | 2022-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $416.51 | 2022-2025 | Trintellix |
| Axsome Therapeutics, INC. | $366.02 | 2023-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $313.21 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $269.58 | 2021-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $116.39 | 2022-2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $78.21 | 2025 | Azstarys |
| Acadia Pharmaceuticals INC | $73.88 | 2023-2024 | Nuplazid |
| E.R. Squibb & Sons, L.L.C. | $55.18 | 2024-2025 | Cobenfy |
| Sage Therapeutics, LLC | $49.22 | 2023 | |
| Ucb, INC. | $42.10 | 2022 | |
| Janssen Biotech, INC. | $31.40 | 2021-2022 | |
| Livanova USA, INC. | $21.68 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Eisai INC. | $19.58 | 2021 | |
| Almatica Pharma LLC | $18.64 | 2024 | Loreev Xr |
| Noven Therapeutics, LLC | $14.14 | 2024 | Xelstrym, Secuado |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,618.07 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Croglio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.